192 related articles for article (PubMed ID: 17961830)
1. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta.
Gorczynski MJ; Grembecka J; Zhou Y; Kong Y; Roudaia L; Douvas MG; Newman M; Bielnicka I; Baber G; Corpora T; Shi J; Sridharan M; Lilien R; Donald BR; Speck NA; Brown ML; Bushweller JH
Chem Biol; 2007 Oct; 14(10):1186-97. PubMed ID: 17961830
[TBL] [Abstract][Full Text] [Related]
2. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
3. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
Hyde RK; Zhao L; Alemu L; Liu PP
Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
[TBL] [Abstract][Full Text] [Related]
4. Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.
Yang Y; Wang W; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD
Cancer Res; 2002 Apr; 62(8):2232-5. PubMed ID: 11956074
[TBL] [Abstract][Full Text] [Related]
5. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.
Cammenga J; Niebuhr B; Horn S; Bergholz U; Putz G; Buchholz F; Löhler J; Stocking C
Cancer Res; 2007 Jan; 67(2):537-45. PubMed ID: 17234761
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor in the early avian embryo: cloning of Cbfbeta and combinatorial expression patterns with Runx1.
Bollerot K; Romero S; Dunon D; Jaffredo T
Gene Expr Patterns; 2005 Dec; 6(1):29-39. PubMed ID: 16033710
[TBL] [Abstract][Full Text] [Related]
9. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
10. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
11. Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis.
Lukasik SM; Zhang L; Corpora T; Tomanicek S; Li Y; Kundu M; Hartman K; Liu PP; Laue TM; Biltonen RL; Speck NA; Bushweller JH
Nat Struct Biol; 2002 Sep; 9(9):674-9. PubMed ID: 12172539
[TBL] [Abstract][Full Text] [Related]
12. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
[TBL] [Abstract][Full Text] [Related]
13. CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium.
Yan J; Liu Y; Lukasik SM; Speck NA; Bushweller JH
Nat Struct Mol Biol; 2004 Sep; 11(9):901-6. PubMed ID: 15322525
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K; Yamagata T; Mitani K
Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
[TBL] [Abstract][Full Text] [Related]
15. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
16. Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta.
Qiu J; Wong J; Tweardy DJ; Dong S
Oncogene; 2006 Jun; 25(28):3982-93. PubMed ID: 16474840
[TBL] [Abstract][Full Text] [Related]
17. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
18. The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.
Philipot O; Joliot V; Ait-Mohamed O; Pellentz C; Robin P; Fritsch L; Ait-Si-Ali S
PLoS One; 2010 Feb; 5(2):e9425. PubMed ID: 20195544
[TBL] [Abstract][Full Text] [Related]
19. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.
Cunningham L; Finckbeiner S; Hyde RK; Southall N; Marugan J; Yedavalli VR; Dehdashti SJ; Reinhold WC; Alemu L; Zhao L; Yeh JR; Sood R; Pommier Y; Austin CP; Jeang KT; Zheng W; Liu P
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14592-7. PubMed ID: 22912405
[TBL] [Abstract][Full Text] [Related]
20. RUNX1 suppression induces megakaryocytic differentiation of UT-7/GM cells.
Nagai R; Matsuura E; Hoshika Y; Nakata E; Nagura H; Watanabe A; Komatsu N; Okada Y; Doi T
Biochem Biophys Res Commun; 2006 Jun; 345(1):78-84. PubMed ID: 16674921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
